Evaluation of an Integrated Imaging System For In Vivo Detection of Fluorescently Labeled Lesions (NCT02802553)
Evaluation of an Integrated Imaging System (Smart Goggles) For In Vivo Detection of Fluorescently Labeled Lymph Nodes for Breast Cancer: A Pilot Study To Visualize Sentinel Lymph Nodes After Periareolar Injection of Indocyanine Green
🩺 Plain-English Summary (8th-Grade Level)
This is a pilot study to test and characterize the ability of the Smart Goggles system to detect fluorescently labeled sentinel lymph nodes (SLNs). Specifically, this study will test the sensitivity and specificity of the Smart Goggles to detect indocyanine green (ICG) accumulation in sentinel lymph nodes of breast cancer patients after peritumoral injection of ICG (Cardio-GreenTM), under standard-of-care application conditions.
Who can join: Review the eligibility criteria below.
Location: Cleveland Clinic, Case Comprehensive Cancer Center — Cleveland, Ohio
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Cleveland Clinic, Case Comprehensive Cancer Center — Cleveland, Ohio
📞 Contact the Study Coordinator
Phone: (866) 223-8100
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Invasive Breast Cancer
- Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer — Milwaukee, Wisconsin
- Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC — Atlanta, Georgia
- Study of a Shortened Radiation Therapy Schedule in People With Breast Cancer — New York, New York
- TRUDI: TDXD+Durva in HER2+/Low IBC — Boston, Massachusetts
- Sacituzumab Govitecan In TNBC — Boston, Massachusetts
Explore by condition: All Invasive Breast Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.